Genetic Technologies (ASX:GTG) Total Current Liabilities: A$4.20 Mil (As of Jun. 2024)


What is Genetic Technologies Total Current Liabilities?

Genetic Technologies ASX:GTG Total Current Liabilities is A$4.20 Mil as of Jun. 2024.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Genetic Technologies's total current liabilities for the quarter that ended in Jun. 2024 was A$4.20

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Genetic Technologies Total Current Liabilities Related Terms

Genetic Technologies Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Total Current Liabilities Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 1.41 3.81 3.31 4.20

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 3.42 0.00 4.20 0.00

Genetic Technologies Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Genetic Technologies's Total Current Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.031+0.852
+Other Current Liabilities+Current Deferred Liabilities
=0.57+0.742
=4.20

Genetic Technologies's Total Current Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.031+0.852
+Other Current Liabilities+Current Deferred Liabilities
=0.57+0.742
=4.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of A$4.20 Mil mean?
Genetic Technologies (ASX:GTG) has a Total Current Liabilities of A$4.20 Mil as of Jun. 2024. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Genetic Technologies and its competitors.
Is Genetic Technologies' Total Current Liabilities too high?
Genetic Technologies' current Total Current Liabilities is A$4.20 Mil.
How does Genetic Technologies' Total Current Liabilities compare to LDDD and NOTV?
Genetic Technologies' Total Current Liabilities of A$4.20 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Diagnostics & Research company?
A good Total Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Genetic Technologies and its competitors. Genetic Technologies's current Total Current Liabilities is A$4.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Total Current Liabilities of A$4.20 Mil. The current Total Current Liabilities is A$4.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Total Current Liabilities is A$4.20 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.